Single-cell mapping initiatives increasingly powering artificial intelligence and biomedical research face scrutiny over significant demographic biases, according to a July 20 study published in Cell Genomics. Researchers from the Icahn School of Medicine at Mount Sinai, led by Dr. Kuan-lin Huang, conducted a systematic audit of three major genomic repositories: the Human Cell Atlas, the Human Tumor Atlas Network, and the PsychAD Consortium. The analysis reveals that these foundational datasets, intended as universal biological references, disproportionately favor European ancestry while leaving Asian, African, and Latino populations underrepresented. The team examined over 13,500 samples, cross-referencing reported ancestry, race, ethnicity, and sex against global population metrics and disease-specific incidence data. The audit uncovered two critical gaps. Nearly seventy percent of samples lacked any recorded ancestry information. Among datasets with complete demographic records, European representation exceeded global expectations by approximately sixfold. Tumor and brain disease datasets mirrored these disparities, with European samples comprising roughly sixty-nine and sixty-six percent respectively. Sex-based imbalances in certain cancer categories also extended beyond clinical incidence rates. These demographic deficiencies pose substantial risks to AI-driven healthcare and precision medicine. As single-cell atlases integrate into machine learning training pipelines, biased inputs can propagate systemic inequities into diagnostic algorithms, biomarker discovery, and therapeutic development. Incomplete or skewed demographic data may yield AI models that perform reliably for European populations while failing to generalize across diverse genetic backgrounds. This pattern mirrors longstanding genomic challenges, where risk prediction scores derived predominantly from European cohorts have demonstrated poor transferability to other groups. To address these shortcomings, the study introduces a standardized demographic audit checklist for research consortia. The framework outlines best practices for recruitment stratification, continuous demographic tracking, sample balancing, and post-model evaluation across ancestry and sex categories. Institutionalizing these protocols enables the field to transition from volume-centric data collection to equitable, clinically actionable resource development. The research team, comprising investigators from the University of Oxford, the University of North Carolina at Charlotte, and Saint Louis University, acknowledges methodological boundaries. The analysis relies on self-reported demographic fields rather than direct genetic sequencing, and broad categorical labels may not capture full ancestral complexity. The audit focused exclusively on three primary public consortia, leaving regional datasets unevaluated. Future iterations will expand to additional repositories, monitor representation trends, and directly assess AI model performance disparities across populations. The findings underscore that representational fairness is a technical prerequisite for robust biomedical innovation. As single-cell technologies accelerate therapeutic discovery, ensuring reference atlases accurately reflect global biological diversity remains essential for reliable science and equitable clinical translation.